Search

T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy

This press release is originally found here: http://prn. to/2YF7Js3

THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

Abstract & Case Report submission

Late-breaking case report submission is now closed.

Read more

EHA-EBMT 3rd European CAR T-cell Meeting (Virtual)

Dates: February 4-6, 2021

Chairs: H Einsele (EHA) & C Chabannon (EBMT)

For the 3rd time now the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT) jointly organized the European CAR T-cell Meeting; this year in…

Read more

EHA-EBMT CAR T-cell Meeting

On this page, you can browse and/or download the 7th European CAR T-cell Meeting Sponsor Program. If the Sponsor Program does not display correctly, please click here or download the file.

Read more

Highlights from the SWG

SWG Committee meetingsIn 2023, the SWG Committee held meetings on:

February 21, 2023—online
April 6, 2023—in The Hague
June 8, 2023—at the EHA Congress 2023 in Frankfurt
In addition, an SWG Chairs and Committee Meeting was held on September 29, 2023, in The Hague.…

Read more

Abstract submission & Awards

Abstract and Case Report submission is now closed. Abstract awardsIntroduced in 2021 and after 3 editions, we are excited to announce the 4th Emerging Investigators EHA-EBMT Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy 2024.

Read more